Cellular uptake of neutral phosphorodiamidate morpholino oligomers

Current Pharmaceutical Biotechnology

Volumn 10, Issue 6, 2009, Pages 579-588

  Iversen, Patrick L ^b   Aird, Katherine M ^b   Wu, Rebecca ^b   Morse, Michael M ^b   Devi, Gayathri R ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA GLOBIN; MESSENGER RNA PRECURSOR; OLIGOMER; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CANCER CELL; CELL TRANSFORMATION; CONTROLLED STUDY; DENDRITIC CELL; DRUG DISTRIBUTION; DRUG SCREENING; DRUG UPTAKE; EMBRYO; ENZYME INHIBITION; GENE TARGETING; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INTERNALIZATION; INTRACELLULAR TRANSPORT; MALE; MONOCYTE; MOUSE; NONHUMAN; RNA SPLICING; T LYMPHOCYTE; TRANSPORT KINETICS;

B-LYMPHOCYTES; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; DENDRITIC CELLS; HUMANS; MONOCYTES; PHOSPHOROTHIOATE OLIGONUCLEOTIDES; T-LYMPHOCYTES;

EID: 71749108789     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920109789069279     Document Type: Article

References (53)

1. Summerton, J. and Weller, D. (1997) Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev., 7, 187-195. (Pubitemid 27323077)
2. Summerton, J. (1999) Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta., 10(1489), 141-158.
3. Giles, R.V.; Spiller, D.G.; Clark, R.E. and Tidd, D.M. (1999)Antisense morpholino oligonucleotide analog induces missplicing of C-myc mRNA. Antisense Nucleic Acid Drug Dev., 9, 213-220.
4. Hudziak, R.M.; Summerton, J.; Weller, D.D. and Iversen, P.L. (2000) Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev., 10, 163-176.
5. Ghosh, C.; Stein, D.; Weller, D. and Iversen, P. (2000) Evaluation of antisense mechanisms of action. Methods Enzymol, 313, 135-143.
6. Devi, G.R.; Beer, T.M.; Corless, C.L.; Arora, V.; Weller, D.L. and Iversen, P.L. (2005)In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res., 15(11), 3930-3938.
7. Iversen, P.L.; Arora, V.; Acker, A.J.; Mason, D.H. and Devi, G.R. (2003) Efficacy of antisense morpholino oligomer targeted to cmyc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin. Cancer Res., 9, 2510-2519.
8. Arora, V.; Devi, G.R. and Iversen, P.L. (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr. Pharm. Biotechnol., 5, 431-439.
9. Qin, G.; Taylor, M.; Ning, Y.Y.; Iversen, P. and Kobzik, L. (2000) In vivo evaluation of a morpholino antisense oligomer directed against tumor necrosis factor-alpha. Antisense Nucleic Acid Drug Dev., 10, 11-16. (Pubitemid 30148185)
10. Arora, V. and Iversen, P.L. (2000) Antisense oligonucleotides targeted to the p53 gene modulate liver regeneration in vivo. Drug Metab. Dispos., 28, 131-138. (Pubitemid 30068995)
11. Kipshidze, N.N.; Kim, H.S.; Iversen, P.; Yazdi, H.A.; Bhargava, B.; New, G.; Mehran, R.; Tio, F.; Haudenschild, C.; Dangas, G.; Stone, G.W.; Iyer, S.; Roubin, G.S. and Leon, M.B.; Moses, J.W. (2002) Intramural coronary delivery of advanced antisense oligonucleotides reduces neointimal formation in the porcine stent restenosis model. J. Am. Coll Cardiol, 15(39), 1686-1691.
12. Ricker, J.L.; Mata, J.E.; Iversen, P.L. and Gattone, V.H. (2002) cmyc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int., 61, S125-131.
13. Knapp, D.C.; Mata, J.E.; Reddy, M.T.; Devi, G.R. and Iversen, P.L. (2003) Resistance to chemotherapeutic drugs overcome by c- Myc inhibition in a Lewis lung carcinoma murine model. Anticancer Drugs, 14, 39-47.
14. Devi, G.R.; Sprenger, C.C.; Plymate, S.R. and Rosenfeld, R.G. (2002) Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo. Prostate, 51, 141-152.
15. Arora, V.; Knapp, D.C.; Reddy, M.T.; Weller, D.D. and Iversen, P.L. (2002) Bioavailability and efficacy of antisense morpholino oligomers targeted to c-myc and cytochrome P-450 3A2 following oral administration in rats. J. Pharm. Sci., 91, 1009-1018.
16. Arora, V.; Hannah, T.L.; Iversen, P.L.; Brand, R.M. (2002) Transdermal use of phosphorodiamidate morpholino oligomer AVI-4472 inhibits cytochrome P450 3A2 activity in male rats. Pharm. Res., 19, 1465-1470.
17. London, C.A.; Sekhon, H.S.; Arora, V.; Stein, D.A.; Iversen, P.L. and Devi, G.R. (2003) A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene. Ther., 10, 823-1382
18. Moulton, H.M.; Hase, M.C.; Smith, K.M. and Iversen, P.L. (2003) HIV Tat peptide enhances cellular delivery of antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev., 13, 31-43. (Pubitemid 36389783)
19. Arora, V.; Cate, M.L.; Ghosh, C. and Iversen, P.L. (2002) Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos., 30, 757-762. (Pubitemid 34671087)
20. Devi, G.R.; Oldenkamp, J.R.; London, C.A. and Iversen, P.L. (2002) Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate, 53, 200-210.
21. Partridge, M.; Vincent, A.; Matthews, P.; Puma, J.; Stein, D. and Summerton, J. (1996) A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev., 6, 169-1675. (Pubitemid 26394876)
22. Ghosh, C. and Iversen, P.L. (2000) Intracellular delivery strategies for antisense phosphorodiamidate morpholino oligomers. Antisense Nucleic Acid Drug Dev., 10, 263-274. (Pubitemid 30692545)
23. Morcos, P.A. (2001) Achieving efficient delivery of morpholino oligos in cultured cells. Genesis, 30, 94-102.
24. Suwanmanee, T.; Sierakowska, H.; Lacerra, G.; Svasti, S.; Kirby, S.; Walsh, C.E.; Fucharoen, S. and Kole, R. (2002) Restoration of human beta-globin gene expression in murine and human IVS2-654 thalassemic erythroid cells by free uptake of antisense oligonucleotides. Mol. Pharmacol., 62, 545-553. (Pubitemid 36329373)
25. Devi, G.R.; Yang, D.H.; Rosenfeld, R.G. and Oh, Y. (2000) Differential effects of insulin-like growth factor (IGF)-binding protein-3 and its proteolytic fragments on ligand binding, cell surface association, and IGF-I receptor signaling. Endocrinology, 141, 4171-4179.
26. Aird, K.M.; Ding, X.; Baras, A.; Wei, J.; Morse, M.A.; Clay, T.; Lyerly, H.K. and Devi, G.R. (2008)Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression. Mol. Cancer Ther., 7, 38-47.
27. Kang, S.H.; Cho, M.J. and Kole, R. (1998) Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry, 5(37), 6235-6239.
28. Sheibani, N. and Frazier, W.A. (1995)Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc. Natl. Acad. Sci. USA, 18(92), 6788-6792.
29. Laktionov, P.P.; Dazard, J.E.; Vives, E.; Rykova, E.Y.; Piette, J.; Vlassov, V.V. and Lebleu, B. (1999) Characterisation of membrane oligonucleotide-binding proteins and oligonucleotide uptake in keratinocytes. Nucleic Acids Res., 27, 2315-2324.
30. Taylor, M.F.; Paulauskis, J.D.; Weller, D.D. and Kobzik, L. (1997) Comparison of efficacy of antisense oligomers directed toward TNF-alpha in helper T and macrophage cell lines. Cytokine, 9, 672-681.
31. Gray, G.D.; Basu, S. and Wickstrom, E. (1997) Transformed and immortalized cellular uptake of oligodeoxynucleoside phosphorothioates, 3′-alkylamino oligodeoxynucleotides, 2′-O-methyl oligoribonucleotides, oligodeoxynucleoside methylphosphonates, and peptide nucleic acids. Biochem. Pharmacol., 53, 1465-1476. (Pubitemid 27356119)
32. Dunn, W.A.; Hubbard, A.L. and Aronson, N.N. Jr., (1980) Low temperature selectively inhibits fusion between pinocytic vesicles and lysosomes during heterophagy of 125I-asialofetuin by the perfused rat liver. J. Biol. Chem., 255, 5971-5978.
33. Marsh, M. (1984)The entry of enveloped viruses into cells by endocytosis. Biochem. J., 218, 1-10.
34. Stein, C.A. (1997)Controversies in the cellular pharmacology of oligodeoxynucleotides. Antisense Nucleic Acid Drug Dev., 7, 207-209.
35. Hans, S.S.; Hans, B.A.; Dhillon, R.; Dmuchowski, C. and Glover, J. (1998)Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am. Surg., 64, 432-436. (Pubitemid 28208787)
36. Biessen, E.A.; Vietsch, H.; Kuiper, J.; Bijsterbosch, M.K. and Berkel, T.J. (1998) Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol. Pharmacol., 53, 262-269.
37. Yakubov, L.A.; Deeva, E.A.; Zarytova, V.F.; Ivanova, E.M.; Ryte, A.S.; Yurchenko, L.V. and Vlassov, V.V. (1989)Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? Proc. Natl. Acad. Sci. USA, 86, 6454-6458.
38. Loke, S.L.; Stein, C.A.; Zhang, X.H.; Mori, K.; Nakanishi, M.; Subasinghe, C.; Cohen, J. S. and Neckers, L.M. (1989) Characterization of oligonucleotide transport into living cells. Proc. Natl. Acad. Sci. USA, 86(3), 474-478.
39. Benimetskaya, L.; Loike, J.D.; Khaled, Z.; Loike, G.; Silverstein, S.C.; Cao, L.; el Khoury, J.; Cai, T.Q. and Stein, C.A. (1997)Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein. Nat. Med., 3, 414-420.
40. de Diesbach, P.; N'Kuli, F.; Delmee, M. and Courtoy, P.J. (2003) Infection by Mycoplasma hyorhinis strongly enhances uptake of antisense oligonucleotides: a reassessment of receptor-mediated endocytosis in the HepG2 cell line. Nucleic Acids Res., 31, 886-892. (Pubitemid 36240426)
41. Levis, J.T.; Butler, W.O.; Tseng, B.Y. and Ts'o, P.O. (1995)Cellular uptake of oligodeoxyribonucleoside methylphosphonates. Antisense Res. Dev., 5, 251-259.
42. Delong, R.K.; Miller, P.S. (1996)Inhibition of human collagenase activity by antisense oligonucleoside methylphosphonates. Antisense Nucleic Acid Drug Dev., 6, 273-280.
43. Crooke, R.M.; Graham, M. J.; Martin, M.J.; Lemonidis, K.M.; Wyrzykiewiecz, T. and Cummins, L.L. (2000) Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther., 292, 140-149. (Pubitemid 30026364)
44. Kipshidze, N.; Iversen, P.; Keane, E.; Stein, D.; Chawla, P.; Skrinska, V.; Shankar, L.R.; Mehran, R, ; Chekanov, V.; Dangas, G.; Komorowski, R.; Haudenschild, C.; Khanna, A.; Leon, M.; Keelan, M.H. and Moses, J. (2002) Complete vascular healing and sustained suppression of neointimal thickening after local delivery of advanced c-myc antisense at six months follow-up in a rabbit balloon injury model. Cardiovasc Radiat Med., 3, 26-30.
45. Kipshidze, N.; Keane, E.; Stein, D.; Chawla, P.; Skrinska, V.; Shankar, L.R.; Khanna, A.; Komorowski, R.; Haudenschild, C.; Iversen, P.; Leon, M.B.; Keelan, M.H. and Moses, J. (2001) Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv., 54, 247-256.
46. Kipshidze, N.; Keelan, M.H.; Petersen, J.R.; Bachutashvili, I.; Vossoughi, J.; Karanian, J.; Ghosh, C.; Iversen, P.; Roubin, G.S.; Leon, M.B. and Moses, J.W. (2000) Photoactivation of vascular iNOS and elevation of cGMP in vivo: possible mechanism for photovasorelaxation and inhibition of restenosis in an atherosclerotic rabbit models. Photochem. Photobiol., 72, 579-582.
47. Arora, V. and Iversen, P.L. (2001)Redirection of drug metabolism using antisense technology. Curr. Opin. Mol. Ther., 3, 249-257. (Pubitemid 32624574)
48. Stein, D.A.; Skilling, D.E.; Iversen, P.L. and Smith, A.W. (2001) Inhibition of Vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev., 11, 317-325.
49. Nasevicius, A.; Larson, J. and Ekker, S.C. (2000) Distinct requirements for zebrafish angiogenesis revealed by a VEGF-A morphant. Yeast, 17, 294-301.
50. Lacerra, G.; Sierakowska, H.; Carestia, C.; Fucharoen, S.; Summerton, J.; Weller, D. and Kole, R. (2000)Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA, 97, 9591-9596. (Pubitemid 30650820)
51. Suwanmanee, T.; Sierakowska, H.; Fucharoen, S. and Kole, R. (2002) Repair of a splicing defect in erythroid cells from patients with beta-thalassemia/HbE disorder. Mol. Ther., 6, 718-726. (Pubitemid 36054305)
52. Juliano, R.L. and Yoo, H. (2000)Aspects of the transport and delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther., 2, 297-303. (Pubitemid 30436000)
53. Tari, A.M. and Lopez-Berestein, G. (2001) Cellular uptake of antisense oligonucleotides. Curr. Opin. Investig Drugs, 2, 1450-1453.